Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399264 | 0.79 | ADORA2A (0.56) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18521272 | 0.78 | ADORA2A (0.34) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL21127807 | 0.78 | ADORA2A (0.34) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL8906057 | 0.77 | FDPS (0.41) | FDPSHDAC6P2RX7FGFR1FGFR4 | |
| SCHEMBL22399501 | 0.75 | YTHDC1 (0.62) | ADORA2AADORA1YTHDC1 | |
| SCHEMBL1868819 | 0.75 | FDPS (0.44) | FDPSHDAC6P2RX7FGFR1FGFR4 | |
| SCHEMBL24205301 | 0.74 | FLT4 (0.43) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22399527 | 0.74 | CYP1A2 (0.57) | — | |
| SCHEMBL9412751 | 0.73 | FGFR1 (0.55) | FDPSHDAC6P2RX7FGFR1FGFR4 | |
| SCHEMBL29213745 | 0.73 | ADORA2A (0.37) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738074-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | FDPS 2814/4885HDAC6 4269/4885P2RX7 67/4885 |
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | FDPS 2883/4885HDAC6 3545/4885P2RX7 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.